Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

• Status: Recruiting
• Trial end date: 2022-12-31

Summary

This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.

• Phase: Phase 2

Details

• Lead Sponsor: University of California, San Francisco
• Collaborators: Napo Pharmaceuticals, Inc.; Puma Biotechnology, Inc.
• Treatments: Antidiarrheals; Atropine; Atropine sulfate-diphenoxylate hydrochloride drug combination; Diphenoxylate; Loperamide; Trastuzumab